Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD)Original paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Whether clemastine fumarate, an antimuscarinic antihistamine, promotes remyelination in multiple sclerosis, measured by visual evoked potential latency.
Who was studied?
Fifty people with relapsing MS and chronic optic neuropathy, in a randomized, double-blind, placebo-controlled crossover trial.
What were the key findings?
Clemastine met its primary endpoint, shortening visual-evoked-potential latency by about 1.7 milliseconds per eye, the first demonstration of myelin repair in a human MS trial. Fatigue was mildly worsened.
What are the implications?
Remyelination is a measurable, achievable target in MS, and antimuscarinic agents such as clemastine can drive it, complementing immune-directed therapy.